Lite Strategy Inc (LITS) Stock Price, Quote & News

Company Profile

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 369 7100

Website: www.litestrategy.com

Address:

9920 Pacific Heights Blvd., Suite 150, San Diego, United States

HodlMyBeerBud Oct. 6 at 3:49 PM

$LTC.X $LITS $BTC.X $ETH.X

0 · Reply

Statistical Oct. 6 at 2:33 PM

$LITS get fucked nerds

0 · Reply

soccerplayer06 Oct. 6 at 1:59 PM

$LITS extremely undervalued here. $LTC.X

0 · Reply

Zorrelak Oct. 5 at 3:08 AM

$LITS it’s gonna get real LITS. Time is coming.

0 · Reply

MaxProfitTrades Oct. 4 at 11:43 PM

$LITS

0 · Reply

HodlMyBeerBud Oct. 4 at 1:29 PM

$LTC.X $LITS $BTC.X $ETH.X

1 · Reply

stick_to_stocks Oct. 4 at 10:03 AM

$LITS few big slaps which went surely unnoticed but expecting a +30-50% medium term

0 · Reply

TheRealBigDuke Oct. 3 at 6:28 PM

$LITS Gov needs to open for the ETF's to get approved?

1 · Reply

R3JS Oct. 3 at 5:51 PM

$LITS amazing buy today free money 💰

0 · Reply

Statistical Oct. 3 at 2:25 PM

$LITS so hilarious to see how badly this backfired on litecoin retail investors. You lost everything within 3 weeks and the shorts are all able to cover with little price increase because this is a scam of a company and free money for shorts. This company and anyone who buys it are fucked.

2 · Reply

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'

Aug 5, 2025, 8:00 AM EDT - 2 months ago

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

Jul 24, 2025, 8:00 PM EDT - 2 months ago

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

Jul 22, 2025, 4:35 PM EDT - 2 months ago

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Jul 18, 2025, 1:22 PM EDT - 2 months ago

Why Is MEI Pharma Stock Soaring On Friday?

Jul 18, 2025, 8:30 AM EDT - 2 months ago

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

May 13, 2025, 4:05 PM EDT - 5 months ago

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

Feb 12, 2025, 4:12 PM EST - 8 months ago

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

Nov 12, 2024, 4:05 PM EST - 11 months ago

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

Sep 19, 2024, 4:01 PM EDT - 1 year ago

MEI Pharma Reports Fiscal Year End 2024 Cash Position

Aug 12, 2024, 8:30 AM EDT - 1 year ago

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

Jul 22, 2024, 8:30 AM EDT - 1 year ago

MEI Pharma to Consider Strategic Alternatives

May 14, 2024, 10:38 AM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

May 9, 2024, 4:02 PM EDT - 1 year ago

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

Apr 11, 2024, 8:02 AM EDT - 1 year ago

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

Apr 11, 2024, 8:00 AM EDT - 1 year ago

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

Apr 10, 2024, 8:00 AM EDT - 1 year ago

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

$MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia$

Mar 26, 2024, 8:00 AM EDT - 1 year ago

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Feb 13, 2024, 5:05 PM EST - 1 year ago

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Jan 16, 2024, 5:00 PM EST - 1 year ago

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

Dec 11, 2023, 12:00 PM EST - 1 year ago

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Nov 9, 2023, 4:05 PM EST - 2 years ago

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

Nov 8, 2023, 8:00 AM EST - 2 years ago

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

Nov 6, 2023, 4:57 PM EST - 2 years ago

MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

Nov 2, 2023, 9:00 AM EDT - 2 years ago

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

Nov 1, 2023, 9:00 AM EDT - 2 years ago

MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

Oct 17, 2023, 5:33 PM EDT - 2 years ago

MEI Pharma Recommends Stockholders Not to Consent

Oct 2, 2023, 6:00 AM EDT - 2 years ago

MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

Sep 28, 2023, 5:00 PM EDT - 2 years ago

MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions

Sep 26, 2023, 7:47 PM EDT - 2 years ago

MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript

Sep 26, 2023, 4:02 PM EDT - 2 years ago

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

Sep 21, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

Sep 18, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car

Aug 16, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

Jul 23, 2023, 2:30 PM EDT - 2 years ago

MEI Pharma Announces Results of Special Meeting of Stockholders

Jul 19, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

Jul 18, 2023, 9:00 AM EDT - 2 years ago

MEI Pharma Responds to Anson and Cable Car

Jul 17, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

Jul 13, 2023, 4:05 PM EDT - 2 years ago

MEI Pharma Postpones Special Meeting of Shareholders

Jul 11, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

Jul 7, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals

Jul 5, 2023, 8:30 AM EDT - 2 years ago

ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

Jul 5, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals

Jun 29, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

Jun 15, 2023, 12:08 PM EDT - 2 years ago

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

Jun 14, 2023, 7:01 PM EDT - 2 years ago

INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

Jun 13, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

Jun 2, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D.

Jun 1, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Board of Directors Rejects Unsolicited Proposal

May 30, 2023, 5:40 PM EDT - 2 years ago

MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal

HodlMyBeerBud Oct. 6 at 3:49 PM

$LTC.X $LITS $BTC.X $ETH.X

0 · Reply

Statistical Oct. 6 at 2:33 PM

$LITS get fucked nerds

0 · Reply

soccerplayer06 Oct. 6 at 1:59 PM

$LITS extremely undervalued here. $LTC.X

0 · Reply

Zorrelak Oct. 5 at 3:08 AM

$LITS it’s gonna get real LITS. Time is coming.

0 · Reply

MaxProfitTrades Oct. 4 at 11:43 PM

$LITS

0 · Reply

HodlMyBeerBud Oct. 4 at 1:29 PM

$LTC.X $LITS $BTC.X $ETH.X

1 · Reply

stick_to_stocks Oct. 4 at 10:03 AM

$LITS few big slaps which went surely unnoticed but expecting a +30-50% medium term

0 · Reply

TheRealBigDuke Oct. 3 at 6:28 PM

$LITS Gov needs to open for the ETF's to get approved?

1 · Reply

R3JS Oct. 3 at 5:51 PM

$LITS amazing buy today free money 💰

0 · Reply

Statistical Oct. 3 at 2:25 PM

2 · Reply

soccerplayer06 Oct. 3 at 11:50 AM

$LITS with no ETF yet, Lite Strategy continues to be the only way for institutions in the US to gain exposure to litecoin. Under $3, this is a no brainer purchase. $LTC.X

0 · Reply

soccerplayer06 Oct. 3 at 10:36 AM

$LTC.X added more here. only a matter of time before moon time. $LITS

0 · Reply

ACInvestorBlog Oct. 3 at 5:30 AM

$LITS Insider buying. This company is the $LTC.X treasury reserve play https://www.sec.gov/Archives/edgar/data/1262104/000119312525228265/xslF345X05/ownership.xml

0 · Reply

FilingTracker Oct. 2 at 8:02 PM

$LITS Insider buy: https://www.sec.gov/Archives/edgar/data/1262104/000119312525228265/xslF345X05/ownership.xml

0 · Reply

DIMOHolder Oct. 2 at 7:25 PM

$LITS price predictions for next week here?

0 · Reply

ACInvestorBlog Oct. 2 at 7:22 PM

$LTC.X Litecoin +15% !! $LITS is the play !!! Lite Strategy (NASDAQ: LITS) is the world’s largest Litecoin Treasury Company The company holds 929,548.46 LTC Holdings

0 · Reply

R3JS Oct. 2 at 6:20 PM

$LITS I don’t get why they haven’t added the 100M on the dip

1 · Reply

TheRealBigDuke Oct. 2 at 5:51 PM

$LITS What's the new pps valuation going to be? Any guesses

0 · Reply

Criszpy Oct. 2 at 4:00 PM

$LITS lol

0 · Reply

Statistical Oct. 2 at 3:16 PM

$LITS you are all fucked

1 · Reply

Jimmydeanbutnotsausage Oct. 2 at 1:51 PM

$LITS LITS AND $LTC WILL HAVE ITS DAY. ALT SZN IS COMING

0 · Reply

soccerplayer06 Oct. 2 at 11:36 AM

$LTC.X Haters gonna hate, but litecoin keeps growing in all the right metrics. Price adjustment to actual value is coming. $LITS

1 · Reply

Market Cap	91.28M
Revenue (ttm)	0.00
Net Income (ttm)	-15.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,049,000
Avg Vol	1,040,606
Day's Range	N/A - N/A
Shares Out	35.66M
Stochastic %K	68%
Beta	0.36
Analysts	Hold
Price Target	N/A